2021
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.Peer-Reviewed Original ResearchConceptsOvarian function suppressionPositive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerBreast cancerPremenopausal womenPatient preferencesPremenopausal Hormone Receptor-Positive Breast CancerAdjuvant gonadotropin‐releasing hormone analoguesHR-positive breast cancerGonadotropin-releasing hormone analogueDiscontinuation of GnRHaThird of patientsChi-square testMonthly goserelinClinical characteristicsTreatment toxicityVaginal drynessClinicopathologic characteristicsGnRH analoguesHot flashesSurgical ablationResultsA totalMedical recordsGnRHaDelay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
Vaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.Peer-Reviewed Original ResearchConceptsEndocrine therapy adherenceTherapy adherenceHormone receptor-positive breast cancerAdjuvant endocrine therapy adherenceReceptor-positive breast cancerOral endocrine therapyBreast cancer survivorsBreast cancer patientsSelf-reported adherencePatient-centered factorsBrief behavioral interventionCross-sectional associationsPotential therapeutic targetMaladaptive health behaviorsEndocrine therapyMedication nonadherenceCancer survivorsCancer patientsRisk factorsBreast cancerTherapeutic targetHealth behaviorsPatientsBehavioral interventionsSurvivorsBPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer
Sukumar J, Quiroga D, Kassem M, Grimm M, Shinde N, Appiah L, Palettas M, Stephens J, Cherian M, Stover D, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer. Journal Of The National Comprehensive Cancer Network 2021, 19: bpi21-008. DOI: 10.6004/jnccn.2020.7759.Peer-Reviewed Original Research
2017
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data
Orchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCross-Sectional StudiesDietDrug-Related Side Effects and Adverse ReactionsFemaleHumansInflammationInterleukin-17Interleukin-6Middle AgedPilot ProjectsPostmenopauseQuality of LifeReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeConceptsBreast cancer survivorsBody mass indexQuality of lifeLower IL-6Cancer survivorsDiet qualityIL-6Breast cancerTNFR-2QOL measuresEndocrine receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerMidwestern cancer centerModifiable lifestyle factorsSerum proinflammatory cytokinesCancer Therapy-BreastHealthy Eating IndexAromatase inhibitor treatmentCross-sectional analysisEndocrine subscaleOverall HEIPrior chemotherapyPostmenopausal womenPrimary therapyPhase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerDay 1Hormone receptor-positive breast cancerReceptor-positive breast cancerPhase Ib studyPhase II doseProgression-free survivalPositive breast cancerOverall response rateHeat shock protein 90 inhibitorNegative breast cancerCycle 1Shock protein 90 inhibitorsPoor outcomeStandard doseAndrogen receptorHsp90 client proteinsHeat shock protein 90Ib studyResponse durationToxicity profilePaclitaxel resistanceClient proteinsDay 7